Valeant Pharmaceuticals International Inc. (NYSE:VRX) was down 2.2% during mid-day trading on Tuesday . The company traded as low as $26.33 and last traded at $26.51, with a volume of 10,963,434 shares. The stock had previously closed at $27.10.

A number of equities research analysts have issued reports on VRX shares. Wells Fargo & Co. reiterated an “underperform” rating and issued a $27.50 target price (down previously from $29.00) on shares of Valeant Pharmaceuticals International in a research report on Friday, May 27th. BMO Capital Markets reiterated a “hold” rating and issued a $44.00 target price on shares of Valeant Pharmaceuticals International in a research report on Friday, May 27th. S&P Equity Research reiterated a “buy” rating on shares of Valeant Pharmaceuticals International in a research report on Sunday, May 29th. Susquehanna reiterated a “hold” rating and issued a $105.00 target price on shares of Valeant Pharmaceuticals International in a research report on Sunday, May 29th. Finally, Piper Jaffray Cos. reiterated a “sell” rating on shares of Valeant Pharmaceuticals International in a research report on Sunday, May 29th. Six equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $56.09.

The company has a 50 day moving average of $27.65 and a 200 day moving average of $29.13. The firm’s market capitalization is $9.15 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last released its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.48 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 9.29% and a positive return on equity of 46.59%. The business earned $2.42 billion during the quarter, compared to analyst estimates of $2.47 billion. During the same quarter last year, the company posted $2.14 earnings per share. The company’s revenue was down 11.4% on a year-over-year basis. On average, equities analysts expect that Valeant Pharmaceuticals International Inc. will post $6.53 earnings per share for the current year.

In other Valeant Pharmaceuticals International news, Director Argeris N. Karabelas purchased 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 11th. The shares were acquired at an average cost of $24.65 per share, for a total transaction of $98,600.00. Following the completion of the purchase, the director now owns 20,726 shares of the company’s stock, valued at approximately $510,895.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 16.37% of the stock is currently owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Top Ace Asset Management Ltd purchased a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth about $2,630,000. Commonwealth Equity Services Inc increased its stake in shares of Valeant Pharmaceuticals International by 103.3% in the first quarter. Commonwealth Equity Services Inc now owns 14,721 shares of the specialty pharmaceutical company’s stock worth $387,000 after buying an additional 7,481 shares during the last quarter. Virginia Retirement System purchased a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth about $1,685,000. IFP Advisors Inc increased its stake in shares of Valeant Pharmaceuticals International by 12.7% in the first quarter. IFP Advisors Inc now owns 171,941 shares of the specialty pharmaceutical company’s stock worth $4,522,000 after buying an additional 19,369 shares during the last quarter. Finally, CQS Cayman LP purchased a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth about $2,630,000. Institutional investors and hedge funds own 63.60% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.